{"analyses":[{"ciLowerLimit":"0.131","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.357","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.216","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Here \"NA\" indicates that median and upper limit of 95% CI was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"31.24","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"16.59","upperLimit":"24.67","value":"20.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"PFS: time between date of randomization and date of disease progression, as assessed by IRC, or date of death due to any cause, whichever occurs first, regardless of use of subsequent anti-cancer therapy prior to PD or death using iWCLL2008 criteria : New enlarged lymph nodes \\>15 mm, new hepatomegaly or splenomegaly, or other organ infiltrates, bone lesion, ascites or pleural effusion due to CLL; \\>=50% increase in longest diameter (LDi) from nadir in existing lymph node (LDi \\>15 mm) or \\>=50% increase from nadir in sum of diameters of multiple nodes (and at least 1 node with LDi \\>15 mm); \\>=50% increase from nadir in enlargement of liver/spleen; \\>=50% increase from baseline in lymphocyte count (ALC; to \\>=5\\*10\\^9/L); or \\>=50% increase from nadir in ALC in \\>=2 serial assessments if ALC is \\>=30000\\*10\\^9/L and lymphocyte doubling time is rapid unless considered treatment-related lymphocytosis; new cytopenia attributable to CLL; transformation to more aggressive histology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) analysis set included all randomized participants who were analyzed according to assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 2 years 10 months","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}